This apart, strong pent-up demand, plethora of new models, lower interest on auto loans and a resilient economy leading to higher consumer confidence contributed to the big push.
The pickup boom was evident. Detroit�� Big Three, General Motors Company (GM), Ford Motor Company (F) and Chrysler, sold 157,480 full-size pickup trucks during the month, up 25% from Jun last year. As a result, average prices of pickups went up 2% year-over-year to $40,361 in Jun, as Kelley Blue Book has revealed.
No doubt, there would be a strong pent up demand, as average age of vehicles on U.S. roads is more then 11 years now. Its worth to mention that interest on auto loans was at near historic low in June. According to Bankrate.com, the average rate on a four-year car loan is 2.7%. The low rate is sustainable for a near term, as Fed Chairman Ben Bernanke has pledged to maintain short-term interest rates at record lows until the unemployment rate reaches 6.5%.
Best Transportation Stocks To Invest In Right Now: Allegheny Technologies Incorporated (ATI)
Allegheny Technologies Incorporated engages in the production and sale of specialty metals worldwide. It operates in three segments: High Performance Metals, Flat-Rolled Products, and Engineered Products. The High Performance Metals segment provides various high performance alloys, including nickel- and cobalt-based alloys and super alloys; titanium and titanium-based alloys; zirconium and related alloys, such as hafnium and niobium; other specialty alloys primarily in long product forms of ingots, billets, bars, shapes and rectangles, rods, wires, and seamless tubes; and precision forgings and castings, and machined parts. The Flat-Rolled Products segment provides stainless steel, nickel-based alloys, super alloys, titanium and titanium-based alloys, and specialty alloys in various product forms comprising plates, sheets, engineered strips, and precision rolled strip products, as well as grain-oriented electrical steel sheets. The Engineered Products segment produces carb on alloy steel impression die forgings, and grey and ductile iron castings, as well as provides precision metal processing services, such as grinding, polishing, blasting, cutting, flattening, and ultrasonic testing. The company serves various markets, including aerospace and defense, oil and gas, chemical process, electrical energy, medical, automotive, construction and mining, food equipment and appliances, transportation, electronics, communication equipment, computers, and machine and cutting tools markets; and other markets requiring tools with hardness. Allegheny Technologies Incorporated sells its products through direct sales and independent representatives. The company was founded in 1960 and is based in Pittsburgh, Pennsylvania.
Advisors' Opinion:- [By Lu Wang]
Valuations for mining and metals companies are too expensive and the shares have further to fall should China�� economy weaken, according to Zach Jonson, the director of fund management at ICON Advisers Inc. Allegheny Technologies Inc. (ATI), a Pittsburgh-based steel producer, and Alcoa trade at a price-earnings ratio above 40, the highest among S&P 500 commodity shares, data compiled by Bloomberg show.
- [By John Divine]
Lastly, shares of materials company Allegheny Technologies (NYSE: ATI ) slipped 3.1% for a third straight day of losses. The week's earlier data from China initiated the slump, as investors fear sluggish industrial production in the Far East will either spread to the West or limit demand in high-growth markets abroad. Credit Suisse also lowered its price target for the stock today, citing an increase in nickel supply.
- [By Ben Levisohn]
Investors, however, are showing no signs of letting up on the risk taking. Want evidence? Just look at the top-performing stocks this week. Four of the top-five come from the materials sector, which could benefit from a stronger economy.�Cliffs Natural Resources (CLF), which rose 9.6% this week, Allegheny Technologies (ATI), which gained 7.7%, U.S. Steel (X), which advanced 7.7%, and Dow-exile Alcoa (AA), which finished the week up 7.6% They were joined by PulteGroup (PHM), which rose 7.8% after a delay of a Fannie Mae and Freddie Mac mortgage-fee hike was mooted.
Top 10 Prefered Companies To Invest In 2015: Atlas Resource Partners LP (ARP)
Atlas Resource Partners, L.P. (Atlas Resource Partners), incorporated on October 13, 2011, is an independent developer and producer of natural gas, crude oil and natural gas liquids (NGL), with operations in basins across the United States. The Company is a sponsor and manager of investment partnerships, in which it co-invests, to finance a portion of its natural gas and oil production activities. During the year ended December 31, 2012, its average daily net production was approximately 77.2 million cubic feet equivalent. On December 20, 2012, it completed the acquisition of DTE Gas Resources, LLC from DTE Energy Company. On September 24, 2012, the Company acquired Equal Energy, Ltd.�� (Equal) remaining 50% interest in approximately 8,500 net undeveloped acres included in the joint venture. On July 26, 2012, it completed the acquisition of Titan Operating, L.L.C. On April 30, 2012, it acquired certain oil and natural gas assets from Carrizo Oil & Gas, Inc. In April 2012, it acquired a 50% interest in approximately 14,500 net undeveloped acres in the oil and NGL area of the Mississippi Lime play in northwestern Oklahoma.
Through December 31, 2012, the Company owned production positions in the areas of the Barnett Shale and Marble Falls play in the Fort Worth Basin in northern Texas; the Appalachia basin, including the Marcellus Shale and the Utica Shale; the Mississippi Lime and Hunton plays in northwestern Oklahoma, and the Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana and the Antrim Shale in Michigan. During 2012, the Company had ownership interests in over 525 wells in the Barnett Shale and Marble Falls play and 569.3 billion cubic feet equivalent of total proved reserves with average daily production of 31.9 million cubic feet equivalent. During 2012, the Company had ownership interests in over 10,200 wells in the Appalachian basin, including approximately 270 wells in the Marcellus Shale and 1! 12.6 billion cubic feet equivalent of total proved reserves with average daily production of 35.6 million cubic feet equivalent. During 2012, it owned 21 billion cubic feet equivalent of total proved reserves with average daily production of 1.9 million cubic feet equivalent in the Mississippi Lime and Hunton plays in northwestern Oklahoma. During 2012, the Company had average daily production of 7.8 million cubic feet equivalent in the Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana, and the Antrim Shale in Michigan.
Advisors' Opinion:- [By Joseph Hogue]
Atlas Resource Partners (NYSE: ARP ) offers the lowest cost to DCF and the second-highest yield of the group. The company is active in the Barnett Shale, Appalachian Basin, the Raton Basin, the Black Warrior Basin and the Mississippi Lime with an interest in over 12,000 producing natural gas and oil wells. The partnership's coverage ratio just missed a top rank as well, and the units could be a solid addition. May saw insider purchases by four officers for 52,530 units at an average price of $19.73 per unit with no insider selling in the past twelve months.
Top 10 Prefered Companies To Invest In 2015: NovaBay Pharmaceuticals Inc. (NBY)
NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. Its products include Aganocide compounds comprising NVC-422 that are synthetic molecules for the treatment of impetigo and adenoviral conjunctivitis, as well as for reducing the incidence of urinary catheter blockage and encrustation, and the associated urinary tract infections. The company is also involved in developing NeutroPhase, a solution for cleansing and debriding wounds. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Advisors' Opinion:- [By CRWE]
NovaBay(r) Pharmaceuticals, Inc. (Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide(r) compounds for the local non-systemic treatment and prevention of infections, reported that Tom Paulson, Chief Financial Officer, will present at the Rodman & Renshaw 14th Annual Healthcare Conference held September 9-11, 2012, in New York, NY.
Top 10 Prefered Companies To Invest In 2015: Strayer Education Inc (STRA)
Strayer Education, Inc. provides post-secondary education services. The Company offers a range of academic programs through its wholly owned subsidiary Strayer University, Inc. (the University), both in classroom courses and online via the Internet. Strayer University is an institution of higher learning that offers undergraduate and graduate degree programs in business administration, accounting, information technology, education, health care, public administration and criminal justice at 92 physical campuses in Alabama, Arkansas, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland, Mississippi, New Jersey, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Washington, D.C., and online. As of December 31, 2011, the Company had opened 78 of its campuses. The Company has also developed a robust online education program.
Strayer University offers business, information technology and professional-oriented curricula to equip students with specialized and practical knowledge and skills for careers in business, industry and Government. Its Academic School Deans and Program Curriculum Committees regularly review and revise the University�� course offerings to improve the educational programs and respond to changes in job markets. Strayer University offers graduate programs in Master of Business Administration (M.B.A.); Jack Welch Executive Master of Business Administration (M.B.A.) Degree; Master of Education (M.Ed.) Degree;Master of Health Services Administration (M.H.S.A.) Degree; Master of Public Administration (M.P.A.) Degree; Master of Science (M.S.) Degree (Information Systems, Accounting, Human Resource Management and Management), and Executive Graduate Certificate Programs (Business Administration, Information Systems and Accounting).
Strayer University�� undergraduate programs include Bachelor of Science (B.S.) Degree (Accounting, Information Systems, Economics and Criminal Justice! ); Bachelor of Business Administration (B.B.A.) Degree;Associate in Arts (A.A.) Degree (Accounting, Acquisition and Contract Management, Business Administration, Information Systems, Economics, Marketing and Criminal Justice); Diploma Programs (Accounting, Acquisition and Contract Management, and Information System), and Undergraduate Certificate Programs (Accounting, Business Administration and Information Systems). Each undergraduate degree program includes courses in oral and written communication skills, as well as mathematics and a range of disciplines in the humanities and social sciences. In addition to its degree, diploma and certificate programs, it offers classes to non-degree and non-program students wishing to take courses for personal or professional enrichment. Strayer University students may enroll in courses at more than one campus and take courses online.
Students can take classes online using either a synchronous (real time) or asynchronous (on demand) format. Students may take all of their courses online or may take online courses as a supplement to traditional, classroom-based courses. Tuition for online courses is the same as for campus courses. During the year ended December 31, 2011, Strayer University had over 32,000 students who took classes solely online.
Advisors' Opinion:- [By Bill Smith]
Competition
ESI competes with many other for-profit ventures, including:
Other for-profit educators, such as: Strayer (STRA), Apollo (APOL), DeVry (DV), Capella (CPLA), Corinthian Colleges (COCO), and Career Education Corporation (CECO)Traditional colleges/universitiesCommunity colleges
Sales, EBITDA and Earnings
ESI has steadily increased revenue and earnings. In the last decade they've grown revenue at 20.8%; EBITDA at 34.4%; FCF at 22.5%, and Book Value at 8.5%. - [By Lisa Levin]
Strayer Education (NASDAQ: STRA) shares touched a new 52-week low of $37.61 after the company reported a 17% drop in its Q3 net income. The company also announced its plans to lower its workforce by 20% and close 20 campuses.
- [By Mark Hulbert]
The stocks are C.H. Robinson Worldwide (CHRW) �, a freight-transportation company; chip maker Cirrus Logic (CRUS) �; independent oil company Forest Oil (FST) �; investment bank Greenhill & Co. (GHL) �; Intrepid Potash (IPI) �, a fertilizer company; retailer J.C. Penney (JCP) �; Quest Diagnostics (DGX) �, a medical diagnostic company; Strayer Education (STRA) �, a for-profit college; Tower Group International (TWGP) �, an insurance company; and Windstream Holdings (WIN) �, a rural telecommunications firm.
Top 10 Prefered Companies To Invest In 2015: Endesa SA (ELE.MC)
Endesa SA is a Spain-based holding company engaged in the energy sector. The Company is primarily involved in the generation, distribution and supply of energy from different sources, such as gas, cogeneration and renewables. It also generates, distributes and supplies electricity. The Company is also engaged in real estate operations as well as coal mining. Its business is divided into four lines: Electricity, Gas, Cogeneration and renewables; as well Other activities. The Company operates in such countries as Spain, Portugal, Chile, Brazil, Colombia, Peru, Argentina, Morocco and China, among others. The Company operates a number of subsidiaries worldwide. The Company is a member of Enel Group. Advisors' Opinion:- [By Anna Prior]
Cheniere Energy Inc.(LNG) said Spanish energy company Endesa SA(ELE.MC) agreed to purchase about 1.5 million tons a year of liquified natural gas from the Houston-based company’s planned Corpus Christi export operations. The agreement is for 20 years from the first commercial delivery, which is expected to start as soon as 2018. Shares edged up 2.4% to $58.99 premarket.
Top 10 Prefered Companies To Invest In 2015: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Johanna Bennett]
Two months since becoming chief executive at Forest Laboratories (FRX), and Brenton Saunders is putting his mark on the drug maker.
On Monday, Forest outlined ��roject Rejuvenate,��a plan to cut costs $500 million by 2016, while scaling back research and development efforts and reducing the company�� work force.
It�� been a common story among big pharmaceutical companies. The industry has grown to depend on acquisitions and licensing deals or partnerships with small drug makers rather than in-house efforts to produce the blockbuster products needed to grow sales and offset revenue lost to generic rivals.
Investors seem to approve. At $55.54, the stock surged 8.2% during afternoon market action.
It was actually a pretty busy day for Forest. Though it restructuring plans attracted the most attention, the company also announced the sale of $1 billion of new debt to help fund $400 million in accelerated stock buybacks as part of a larger $1 billion share repurchase plan and a $250 million deal to acquire exclusive rights to the schizophrenia medication Saphris from Merck & Co. (MRK).
Altogether, it could be quite a boon for Forest�� bottom line. Leerink Swann analyst Seamus Fernandez raised his per share earnings estimate for 2015 and 2016 to $2.89 and $3.24 respectively from the previous $1.87 and $1.19. Fernandez writes:
We see several potential accretive Saphris-like opportunities for FRX particularly as companies like MRK partner or exit cost-intensive primary care/specialty categories (e.g., respiratory, antibiotics/antifungal, cardiology, GI, CNS). Incorporating these changes (and assuming no impact to sales ests of FRX’s existing portfolio), our new DCF valuation increases to $63/shr.
Top 10 Prefered Companies To Invest In 2015: Tempur-pedic International Inc (TPX)
Tempur-Pedic International Inc. manufactures, markets, and distributes bedding products in North America and internationally. Its products include pillows, mattresses, and adjustable beds, as well as various cushions and other comfort products. The company sells its mattresses and pillows under the TEMPUR and Tempur-Pedic brand names through furniture and bedding, specialty, and department stores; direct response, Internet, and own stores; chiropractors, medical retailers, hospitals, and other healthcare markets; and third party distributors. Tempur-Pedic International Inc. was founded in 1989 and is based in Lexington, Kentucky.
Advisors' Opinion:- [By Toshiro Hasegawa]
Investors are waiting to see whether Abe can succeed with growth-oriented initiatives to make Japan�� economic recovery sustainable, in the so-called third arrow of his strategy following fiscal stimulus and monetary easing. Exporters led by Toyota Motor Corp. are reliant on a weaker yen to help them meet the outsized profit gains expected by analysts. Topix (TPX) member companies will boost earnings by 26 percent in the next 12 months, compared with the 11 percent growth estimated for the Standard & Poor�� 500 Index, data compiled by Bloomberg show.
- [By Yoshiaki Nohara]
Japanese stocks rose, with the Topix (TPX) index headed for its highest level in three weeks, as investors speculated corporate earnings will beat forecasts.
- [By Anna Kitanaka]
Japanese shares rose, with the Topix (TPX) index closing at its highest level in almost two months, on optimism about earnings in Japan and the U.S. Profits at Topix companies are projected to almost double this quarter.
No comments:
Post a Comment